Presented by Dr Ayça Arçay Öztürk (Institut Jules Bordet, Brussels, Belgium)
In this video, Dr Ayça Arçay Öztürk presents the results of the single-centre, prospective, phase II FAPeCa trial, evaluating [⁶⁸Ga]Ga-FAPI-46 PET/CT for the preoperative assessment of peritoneal carcinomatosis in patients with ovarian or colorectal cancer.
Accurate preoperative mapping of peritoneal carcinomatosis is essential when planning cytoreductive surgery, yet conventional imaging may underestimate tumour burden. In this study, 61 patients underwent FAPI PET/CT, FDG PET/CT and MRI-DWI before diagnostic laparoscopy and/or cytoreductive surgery, with intraoperative and histopathological findings used as the reference standard.
The results showed that FAPI PET/CT had the strongest agreement with the surgico-pathological peritoneal cancer index assessment, a scoring system used to quantify the extent of peritoneal disease. FAPI PET/CT also demonstrated higher sensitivity for detecting peritoneal involvement, although with lower specificity compared with FDG PET/CT and MRI-DWI. Importantly, its performance remained good in patients who had recently received chemotherapy, a clinically challenging setting in which residual disease can be difficult to assess.
These findings support [⁶⁸Ga]Ga-FAPI-46 PET/CT as a promising imaging modality for preoperative mapping of peritoneal carcinomatosis, with potential value for treatment planning and patient selection for cytoreductive surgery.
Reference:
Arçay Öztürk A, et al. Presented at ASCO 2026; Abstract 5553.
Donderdag 12 november 2026
Kontich
Gent
Linter
Onthaal vanaf 18 uur
Programma van 19 tot 22 uur
Kies jouw locatie en schrijf je in
Donderdag 12 november 2026
Kontich
Gent
Linter
Onthaal vanaf 18 uur
Programma van 19 tot 22 uur
Kies jouw locatie en schrijf je in